Phase 2 trials of antiviral pill show promising results in battling COVID-19
UPDATED 1:16 PM PT – Wednesday, March 10, 2021
Two American companies teamed up to produce an anti-viral pill used to combat the coronavirus. According to recent reports, the drug molnupiravirperf performed well in early-stage trials.
Ridgeback Biotherapeutics and Merck said their pill is a five day, at-home treatment aimed to reduce the damage done by the virus as well as cut down on the time it takes to receive a negative test after being infected.
Researchers are optimistic about the pill’s capabilities.
“It might be one of those drugs, fingers crossed, that it doesn’t matter what virus you have,” USF Associate Professor of Pediatrics Medicine Michael Teng Ph.D. stated. “If you have these respiratory symptoms, take this drug, it will probably hit that virus.”
Doctors that have studied the medication are calling it a potential “holy grail.” They noted it could be made available in the next four to five months.